RecruitingNCT04690660

Swiss Postpartum Hypertension Cohort

Swiss Postpartum Hypertension Cohort (Swiss-PPHT)

Sponsor

University Hospital, Basel, Switzerland

Enrollment

480 participants

Start Date

Jun 4, 2020

Study Type

OBSERVATIONAL

Conditions

Postpartum Hypertension (PPHT)

Summary

This open label, prospective observational, single-center registry is to study short-, intermediate-and long-term course of postpartum hypertension and predictors/risk factors associated with long term cardiovascular and renal risk. Current disease management strategies will be evaluated.

Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria4

all women with hypertensive disorders of pregnancy
postpartum hypertension (blood pressure measurements of systolic ≥140 and/or diastolic ≥ 90mmHg or antihypertensive therapy within the first 14 days after delivery)
women with preexisting hypertension or
women on antihypertensive medication

Exclusion Criteria2

delivery \> 14 days
lack of consent to participate in the study, language barriers or lack of general understanding

Interventions

OTHERData collection for parameters of organ damage (cardiac and renal blood markers)

Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.

OTHERData collection for blood pressure (BP)

Clinic blood pressure and 24hour BP Measurements

OTHERHome-based blood pressure management (substudy)

Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.

OTHERBiomarker Profiles (substudy)

Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).

OTHERData collection on patient reported outcomes

Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )

Locations(1)

Medical Outpatient Department and Hypertension Clinic, University Hospital Basel

Basel, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04690660